From Nasdaq: 2025-06-10 18:20:00

OS Therapies Inc. partners with EVERSANA to support U.S. commercialization of OST-HER2, a novel treatment for pediatric lung metastatic osteosarcoma. OST-HER2, based on Listeria monocytogenes, is the first potential new therapy for pediatric osteosarcoma in over four decades. It has FDA designations and a BLA submission expected in Q3 2025. EVERSANA will provide commercialization services for OST-HER2, aiming to expedite access to the therapy. This partnership follows OS Therapies securing a U.S. Patent for OST-HER2 through 2040. OSTX is currently trading at $1.93 on the NYSE American.



Read more at Nasdaq: OS Therapies Taps EVERSANA To Launch First New Pediatric Osteosarcoma Treatment In 40 Years